Delek Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Delek Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$6.55M	Buy	+50,000	New	+$6.44M	0.25%	104

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Delek Group's ALXN Position: Q2 2019 in Review

Delek Group increased its Alexion Pharmaceuticals (ALXN) stake by 17% in Q2 2019, buying an estimated $3.22M and bringing the position to 167,933 shares worth $21.5M. The position accounts for 0.83% of the portfolio, ranked #44.

Delek Group first reported a position in ALXN in Q4 2017 and has held it in 7 quarters since. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

Delek Group held 167,933 shares of Alexion Pharmaceuticals worth $21.5M as of Q2 2019.
Delek Group bought 25,000 Alexion Pharmaceuticals shares in Q2 2019, an estimated $3.22M.
Alexion Pharmaceuticals made up 0.83% of Delek Group's portfolio in Q2 2019, its #44 holding.
Delek Group first reported a position in Alexion Pharmaceuticals in Q4 2017 and has held it in 7 quarters since.
636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.